Pim Kinase Inhibitors

PIM proteins belong to a family of serine/threonine kinases composed of 3 isoforms, PIM1, PIM2 and PIM3, with greatly overlapping functions. Pim kinases play a key role in the cell cycle regulation, having potent anti-apoptotic activity.They also play a role in the homing and migration of metastatic cells.

Increased PIM kinase expression is associated with malignant subtypes of leukemia, lymphoma and a number of sold tumours including pancreatic, colorectal and oesophageal cancers.
 

PIM kinases share many of the same substrates as kinases of the Akt pathway. Thus, a PIM kinase inhibitor is well positioned for combination therapy with inhibitors of the Akt pathway (i.e., inhibitors of EGFR, PI3K, Akt and mTOR) and the mechanism is represented in the figure below.

image006
 

 

 

 

 

 

 

 

 

Inflection is developing unique pan-PIM kinase inhibitors (IBL-100 series) with activity on all three isoforms. The molecules are highly selective for all three PIM isoforms in the low nanomolar to sub-nanomolar range and with no significant activities detected at sub-micromolar concentrations over 400 kinases on a kinome-wide scan. No cardiovascular concerns were found at therapeutic concentrations (in both HERG binding assay and functional patch-clamp electrophysiological assays).

The molecules have been shown to be highly orally available with excellent pharmaceutical properties and have shown activity in a number of preclinical models related to AML and non-small cell lung carcinoma. Further in vitro and in vivo testing is underway to optimally characterise the efficacy profile of this program.

Search

Search - Use spaces to separate your keywords
Image
Inflection Biosciences. Suite 15, Anglesea House Carysfort Avenue, Blackrock,  Co. Dublin.  

 Company registration no. 509046.

© 2017 Inflection Biosciences.   Web Design by Webtrade